Telix Pharmaceuticals Ltd (ASX: TLX) has received regulatory approval from the US Food and Drug Administration (FDA) to expand the indication of its diagnostic agent Illuccix. The approval allows the use of the gallium Ga 68 gozetotide injection kit to select patients with metastatic prostate cancer who may benefit from lutetium-177 PSMA-directed therapy. Illuccix is now the only diagnostic agent for prostate cancer that combines the accuracy of gallium imaging with the reliability and flexibility of Telix's distribution network.
The expanded indication for Illuccix has the potential to improve access to imaging for patients who are candidates for radioligand therapy. The expanded indication will provide doctors with critical information to guide patient management and optimize treatment outcomes. The VISION Phase III study showed that the use of Illuccix helped doctors detect prostate cancer and identify appropriate patients for PSMA-based radioligand therapy.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.